Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIdE trial of sacituzumab govitecan in metastatic triple-negative breast cancer
2022-502369-10-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Unicancer. Primary endpoint: Objective response rate. Planned start Oct 2023; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-502369-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502369-10-00.